Tirotoksikoz Tanı ve Tedavi Yaklaşımları
Özet
Tirotoksikoz, serumda tiroid hormonlarının yüksek bulunmasıyla karakterize, kadınlarda 5 kat daha sık görülen bir metabolizma tablosudur. En sık nedenleri gençlerde Graves hastalığı, yaşlılarda ise toksik multinodüler guatrdır. Klinik olarak kilo kaybı, çarpıntı, halsizlik ve tremor gibi spesifik olmayan semptomlarla ortaya çıkar. Tanı aşamasında baskılanmış TSH düzeyi en hassas göstergeyken; aşikar hipertiroidide T3 ve T4 yüksek, subklinik formda ise normaldir. Ayırıcı tanıda sintigrafi (RAIU) ve ultrasonografi kullanılır. RAIU artışına yol açan Graves ve adenom gibi durumlarda tiyonamidler (Metimazol, PTU), radyoaktif iyot (RAI) veya cerrahi tercih edilir. Tiroidit gibi RAIU düşüklüğü ile seyreden destrüktif tablolarda ise anti-tiroid ilaçların yeri yoktur, tedavi beta-blokerler ve NSAİİ’ler ile semptomatik olarak yürütülür. Küratif cerrahi büyük guatr veya bası semptomlarında uygulanır.
Thyrotoxicosis is a metabolic condition characterized by elevated serum thyroid hormones, occurring 5 times more frequently in women. The most common causes are Graves' disease in young individuals and toxic multinodular goiter in the elderly. Clinically, it presents with non-specific symptoms such as weight loss, palpitations, fatigue, and tremors. In diagnosis, a suppressed TSH level is the most sensitive indicator; while T3 and T4 are elevated in overt hyperthyroidism, they remain normal in subclinical forms. Scintigraphy (RAIU) and ultrasonography are used for differential diagnosis. In conditions causing increased RAIU, such as Graves' and adenoma, thionamides (Methimazole, PTU), radioactive iodine (RAI), or surgery are preferred. Conversely, antithyroid drugs have no role in destructive conditions presenting with low RAIU, like thyroiditis; management is conducted symptomatically with beta-blockers and NSAIDs. Curative surgery is performed for large goiters or compression symptoms.
Referanslar
Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489-499. doi:10.1210/jcem.87.2.8182
Asvold BO, Bjøro T, Nilsen TI, Vatten LJ. Tobacco smoking and thyroid function: a population-based study. Arch Intern Med. 2007; 167(13):1428-1432. doi: 10.1001/archinte.167.13.1428
Holm IA, Manson JE, Michels KB, et al. Smoking and other lifestyle factors and the risk of Graves' hyperthyroidism. Arch Intern Med.2005;165(14):1606-11. doi: 10.1001/archinte.165.14.1606
Nordyke RA, Gilbert FI Jr, Harada AS. Graves' disease. Influence of age on clinical findings. Arch Intern Med 1988; 148(3):626-31. doi: 10.1001/archinte.148.3.626
Trzepacz PT, Klein I, Roberts M, et al. Graves' disease: an analysis of thyroid hormone levels and hyperthyroid signs and symptoms. Am J Med 1989; 87(5):558-561. doi: 10.1016/s0002-9343(89)80614-x.
Krassas GE, Pontikides N, Kaltsas T, et al. Menstrual disturbances in thyrotoxicosis. Clin Endocrinol (Oxf) 1994; 40(5):641-644. doi: 10.1111/j.1365-2265.1994.tb03016.x.
Kidd GS, Glass AR, Vigersky RA. The hypothalamic-pituitary-testicular axis in thyrotoxicosis. J Clin Endocrinol Metab 1979; 48(5):798-802. doi: 10.1210/jcem-48-5-798
Woeber KA. Thyrotoxicosis and the heart. N Engl J Med 1992; 327:94.Ayres J, Rees J, Clark TJ, Maisey MN. Thyrotoxicosis and dyspnoea. Clin Endocrinol (Oxf) 1982; 16(2):65-68. doi: 10.1056/NEJM199207093270206
Boelaert K, Torlinska B, Holder RL, Franklyn JA. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab 2010; 95(6):2715-2726. doi: 10.1210/jc.2009-2495
Davies TF. New thinking on the immunology of Graves' disease. Thyroid Today 1992; 15:1-11.
Brent GA. Clinical practice. Graves' disease. N Engl J Med. 2008;358(24):2594-2605. doi:10.1056/NEJMcp0801880
Radosavljević VR, Janković SM, Marinković JM. Stressful life events in the pathogenesis of Graves' disease. Eur J Endocrinol. 1996;134(6):699-701. doi:10.1530/eje.0.1340699
Laurberg P, Pedersen KM, Vestergaard H, et al. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med. 1991;229(5):415-420. doi:10.1111/j.1365-2796.1991.tb00368.x
Mc Dermott MT, Burman KD, Hofeldt FD, et al. Lithium-associated thyrotoxicosis. Am J Med. 1986;80(6):1245-1248. doi:10.1016/0002-9343(86)90697-2
Carella C, Mazziotti G, Amato G, et al. Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab. 2004;89(8):3656-3661. doi:10.1210/jc.2004-0627
Daniels GH, Vladic A, Brinar V, et al. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab. 2014;99(1):80-89. doi:10.1210/jc.2013-2201
Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, et al. Two Cases of Graves' Disease Following SARS-CoV-2 Vaccination: An Autoimmune/Inflammatory Syndrome Induced by Adjuvants. Thyroid. 2021;31(9):1436-1439. doi:10.1089/thy.2021.0142
Duprez L, Hermans J, Van Sande J, et al. Two autonomous nodules of a patient with multinodular goiter harbor different activating mutations of the thyrotropin receptor gene. J Clin Endocrinol Metab. 1997;82(1):306-308. doi:10.1210/jcem.82.1.3691
Parma J, Duprez L, Van Sande J, et al. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gs alpha genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab. 1997;82(8):2695-2701. doi:10.1210/jcem.82.8.4144
Holzapfel HP, Führer D, Wonerow P, et al. Identification of constitutively activating somatic thyrotropin receptor mutations in a subset of toxic multinodular goiters. J Clin Endocrinol Metab. 1997;82(12):4229-4233. doi:10.1210/jcem.82.12.4441
Pinducciu C, Borgonovo G, Arezzo A, et al. Toxic thyroid adenoma: absence of DNA mutations of the TSH receptor and Gs alpha. Eur J Endocrinol. 1998;138(1):37-40. doi:10.1530/eje.0.1380037
Yoshimura M, Pekary AE, Pang XP, et al. Thyrotropic activity of basic isoelectric forms of human chorionic gonadotropin extracted from hydatidiform mole tissues. J Clin Endocrinol Metab 1994; 78(4):862-866. doi: 10.1210/jcem.78.4.8157712.
Mandel SJ, Lersen PR, Davies TF. Thyrotoxicosis. In:Melmed S, Polonsky KS, Larsen PR, Krononberg HN (eds.) Williams Textbook of Endocrinology. 12th. ed. Phiadelphia: Saunders Elsevier; 2011. p. 362-404.
Wynne AG, Gharib H, Scheithauer BW, et al. Hyperthyroidism due to inappropriate secretion of thyrotropin in 10 patients. Am J Med. 1992;92(1):15-24. doi:10.1016/0002-9343(92)90009-z
Beck-Peccoz P, Brucker-Davis F, Persani L, et al. Thyrotropin-secreting pituitary tumors. Endocr Rev. 1996;17(6):610-638. doi:10.1210/edrv-17-6-610
Rösler A, Litvin Y, Hage C, et al. Familial hyperthyroidism due to inappropriate thyrotropin secretion successfully treated with triiodothyronine. J Clin Endocrinol Metab. 1982;54(1):76-82. doi:10.1210/jcem-54-1-76
Farid NR, Kascur V, Balazs C. The human thyrotropin receptor is highly mutable: a review of gain-of-function mutations. Eur J Endocrinol. 2000;143(1):25-30. doi:10.1530/eje.0.1430025
Volpé R. Subacute (de Quervain's) thyroiditis. Clin Endocrinol Metab. 1979;8(1):81-95. doi:10.1016/s0300-595x(79)80011-0
Nikolai TF, Coombs GJ, McKenzie AK, et al. Treatment of lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis). Arch Intern Med. 1982;142(13):2281-2283. doi:10.1001/archinte.142.13.2281
Lambert M, Unger J, De Nayer P, Brohet C, Gangji D. Amiodarone-induced thyrotoxicosis suggestive of thyroid damage. J Endocrinol Invest. 1990;13(6):527-530. doi:10.1007/BF03348618
Grossmann M, Premaratne E, Desai J, et al. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf). 2008;69(4):669-672. doi:10.1111/j.1365-2265.2008.03253.x
Ahmadieh H, Salti I. Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment. Biomed Res Int. 2013;2013:725410. doi:10.1155/2013/725410
Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol. 2018;4(2):173-182. doi:10.1001/jamaoncol.2017.3064
İremli BG, Şendur SN, Ünlütürk U. Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Postvaccination ASIA Syndrome. J Clin Endocrinol Metab. 2021;106(9):2600-2605. doi:10.1210/clinem/dgab373
Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. doi:10.1089/thy.2016.0229
